<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956836</url>
  </required_header>
  <id_info>
    <org_study_id>HUVirgenRocio</org_study_id>
    <nct_id>NCT03956836</nct_id>
  </id_info>
  <brief_title>Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)</brief_title>
  <acronym>HIPEC-COAG</acronym>
  <official_title>Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytoreductive surgery (CRC) with intraperitoneal hyperthermal chemotherapy (HIPEC) has been&#xD;
      shown to improve survival in selected patients with peritoneal carcinomatosis. 51% of&#xD;
      patients are transfused due to the high intraoperative blood loss caused by surgery and the&#xD;
      appearance of a perioperative coagulopathy attributed to the loss of proteins into the&#xD;
      peritoneal cavity, the high fluid turnover and possibly the action of hyperthermic&#xD;
      chemotherapy. So far, the haemostatic changes described consist of a decrease in the levels&#xD;
      of antithrombin III and the platelet count, as well as in alterations of the usual&#xD;
      coagulation tests. Conventional coagulation tests analyze only the plasmatic phase of&#xD;
      coagulation while viscoelastic tests, such as rotational thromboelastometry (ROTEM),&#xD;
      reproduce the global coagulation process much more faithfully, keeping good correlation with&#xD;
      perioperative bleeding.&#xD;
&#xD;
      Objetive:&#xD;
&#xD;
      The platelet, coagulation, von Willebrand and Factor XIII levels and function have not been&#xD;
      consistently investigate in pre-established (fix) time periods in patients undergoing&#xD;
      elective CRC with hyperthermia. This prospective observational study aimed at investigating&#xD;
      the variations of the values of estándar coagulation test, ROTEM parameters, platelet&#xD;
      function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and&#xD;
      after 4h and 48 after surgery in 40 patients undergoing CRC. A control group (N=40 blood&#xD;
      donors) will be also obtained by baseline comparasion and to obtain local reference ranges.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study aimed at investigating the variations of the values of&#xD;
      estándar coagulation test, ROTEM parameters, platelet function assay (PFA-100), von&#xD;
      Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in&#xD;
      40 patients undergoing CRC. A control group (N=40 blood donors) will be also obtained by&#xD;
      baseline comparasion and to obtain local reference ranges.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">March 8, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>Variations of CT-ROTEM</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in clotting time of ROTEM from baseline (preoperative) to 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of MCF-ROTEM</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in maximum clotting firmness of ROTEM 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of PFA-100</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in COL-EPI (platelet function) from of 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of Factor XIII</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in factor XIII Concentration of clotting factor from baseline (preoperative) of 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of von Willebrand</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in von Willebrand Concentration from 48 hours post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion of red blood cells</measure>
    <time_frame>20 days</time_frame>
    <description>number of packed red blood cells and percentage of transfused patients</description>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Coagulation Disorder</condition>
  <condition>Carcinomatosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII</intervention_name>
    <description>ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC</description>
    <other_name>ROTEM, PFA-100</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis of peritoneal surface malignancy of the ovarian and/or colo&#xD;
        origin undergoing complete cytoreductive surgery (zero) combined with Hyperthermic&#xD;
        Intraperitoneal Chemotherapy (HIPEC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. - Consecutive patients with peritoneal surface malignancy treated with cytoreductive&#xD;
             surgery and HIPEC in the Department of Surgery of Virgen del Rocio General Hospital&#xD;
&#xD;
          2. -All patients gave written informed consent.&#xD;
&#xD;
          3. -Age above 18 years and Karnofsky performance status scale 450%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. - Exclusion criteria: were severe cardiovascular or respiratory disease,&#xD;
&#xD;
          2. - Lower hemoglobin than 10,0 g/dL , platelet count 100,000/mm3,&#xD;
&#xD;
          3. - Renal or hepatic failure,&#xD;
&#xD;
          4. - Pregnancy,&#xD;
&#xD;
          5. - Multiple partial intestinal obstruction or extensive involvement of the surface of&#xD;
             the small bowel as well as distant and non-resectable metastases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Antonio M. Puppo Moreno</investigator_full_name>
    <investigator_title>Critical Care Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

